Description
release form concentrated infusion solution
Packing
5 ml – dark glass ampoules (5) – plastic pallets (2) – packs of cardboard.
Pharmacological action
Cavinton – a drug that improves cerebral circulation, cerebral metabolism and rheological properties of blood.
Has a cerebroprotective effect. Reduces the severity of damaging cytotoxic reactions, caused by stimulating amino acids inhibits the functional activity of both cellular transmembrane sodium and calcium channels, as well as NMDA and AMPA receptors. Potentiates the neuroprotective effect of adenosine. Stimulates brain metabolism, enhances the absorption and absorption of glucose and oxygen by the brain. Stimulates glucose transport through the BBB, shifts glucose metabolism to an energetically more beneficial aerobic direction. Selectively inhibits Ca2 + -calmodulin-dependent cGMP-phosphodiesterase, increases the concentration of cAMP and cGMP in the brain tissue, as well as the concentration of ATP and the ratio of ATP / AMP. It stimulates cerebral metabolism of norepinephrine and serotonin, stimulates the ascending norepinephrine system, and has an antioxidant effect.
The drug selectively enhances cerebral blood flow: increases the cerebral fraction of the minute volume reduces the resistance of the vessels of the brain, without affecting the parameters of the general blood circulation (blood pressure, minute volume, heart rate, OPSS).
Does not cause the robbery phenomenon, on the contrary, with its use, the blood supply to the ischemic, but still viable area with low perfusion increases, the phenomenon of reverse robbery.
Improves the tolerance of hypoxia by brain cells, promoting the transport of oxygen to tissues due to a decrease in the affinity of red blood cells for it.
The drug improves microcirculation of the brain, inhibits platelet aggregation, reduces pathologically increased blood viscosity, increases the deformability of red blood cells and blocks their absorption of adenosine.
Indications
In neurology, acute and chronic cerebrovascular insufficiency (transient ischemia, progressive stroke, post-stroke conditions, vascular dementia, cerebral arteriosclerosis, post-traumatic and hypertensive encephalopathy, vertebro-basilar insufficiency) mental and neurological disorders in patients with cerebrovascular insufficiency (including impaired memory, dizziness, headache, aphasia, apraxia, motor disorders).
In ophthalmology – vascular diseases of the eye (atherosclerosis, angiospasm of the choroid and retina, degenerative diseases of the choroid, retina or macula, arterial and venous thrombosis or embolism, secondary glaucoma).
In ENT practice – hearing loss (vascular, toxic or age-related), Meniere’s disease, cochleovestibular neuritis, tinnitus, dizziness (labyrinth origin), vasovegetative manifestations of menopause syndrome.
Contraindications
Pregnancy lactation severe forms of heart failure and cardiac arrhythmias hypersensitivity to vinpocetine or other components of the drug.
Special instructions
Cavinton does not have hepato- and nephrotoxic effects, therefore, when prescribing the drug to patients with liver and kidney diseases, a dosage regimen correction is not required.
Use in pediatrics
Do not recommend prescribing the drug to children under the age of 18 due to a lack of experience with Cavinton in this category of patients.
Composition
1 ml contains 5 mg vinpocetine
Dosage and administration
The initial daily dose is 20 mg in a dilution of 500-1000 ml of solution for infusion, intravenously, slowly (drip).
Maximum dose up to 1 mg / kg body weight. A course of 10-21 days with the transition to oral administration of a tablet form of Cavinton 1-2 tablets 3 times a day.
Side effects of
From the cardiovascular system: possible manifestations of existing arrhythmia.
From the digestive system: nausea, heartburn, dry mouth.
From the central nervous system: headache, dizziness, sleep disturbance, weakness.
Allergic reactions: skin rash, urticaria.
Skin reactions: flushing of the skin.
Drug interaction
With simultaneous use, no interaction with beta-blockers (chloranolol, pindolol), clopamide, glibenclamide, digoxin, acenocoumarol or hydrochlorothiazide is observed.
In rare cases, concomitant use with alpha-methyldopa is accompanied by some increase in the hypotensive effect, with the use of such a combination, regular monitoring of blood pressure is necessary.
Despite the lack of evidence of interoperability, caution is advised when given simultaneously with centrally acting drugs and antiarrhythmics.
Pharmaceutical interactions
Concentrate for solution for infusion and heparin are chemically incompatible, therefore it is forbidden to administer them in the same infusion mixture, however, treatment with anticoagulants and vinpocetine can be carried out simultaneously.
Concentrate for solution for infusion is incompatible with infusion solutions containing amino acids, so they can not be used for dilution Cavinton.
overdose
Currently, overdose on Cavinton ® is limited.
Treatment: carrying out symptomatic therapy.
Storage conditions
The product should be stored in a dark place away from children at 15 ° C to 30 ° C.
Shelf life
5 years.
Conditions of sale from
pharmacies Prescription
dosage form
infusion solution
Possible product names
CAVINTON 0.005 / ML 5ML N10 AMP
CAVINTON 0.005 / ML 5ML N10 AMP CONCESS D / R-RA D / INF
Cavinton 5mg. d / prg. solution for infusion 5ml Amp.t / s X10 B M (R)
Cavinton ampoules 25 mg, 5 ml, 10 pcs.
Cavinton conc d / inf 5mg / ml amp 5ml x 10
